Safinamide
• Applied to MHLW for Parkinson’s disease on October 23
• Out-licensed to Eisai
Ziprasidone
• Another product of our antipsychotic drug in addition to SYCREST
• Will be applied to MHLW in FYE March 2020
OP0595
• AMED* has adopted for CiCLE program on October 22
• Develop as a single agent for antibacterial drug using government subsidies
• Contribute to defeat antimicrobial resistance
* AMED promotes integrated research and development in the field of medicine, from basic research to clinical trials.
ME5343
• A novel agricultural insecticide, Inscalis (Afidopyropen), received EPA registration in the U.S. by BASF (licensee) on October 2
• Received milestone payment
Has promising pipelines, details on Slide 37
Allocate R&D expenses effectively to key growth drivers
Safinamide
• Applied to MHLW for Parkinson’s disease on October 23
• Out-licensed to Eisai
Ziprasidone
• Another product of our antipsychotic drug in addition to SYCREST
• Will be applied to MHLW in FYE March 2020
OP0595
• AMED* has adopted for CiCLE program on October 22
• Develop as a single agent for antibacterial drug using government subsidies
• Contribute to defeat antimicrobial resistance
* AMED promotes integrated research and development in the field of medicine, from basic research to clinical trials.
ME5343
• A novel agricultural insecticide, Inscalis (Afidopyropen), received EPA registration in the U.S. by BASF (licensee) on October 2
• Received milestone payment
KM BiologicsHas promising pipelines, details on Slide 37